Adam Tibbles

Adam Tibbles is a notable inventor based in Cambridge, GB. He has made significant contributions to the field of biotechnology, particularly in the development of recombinant polypeptide therapeutics. His innovative work focuses on engineered O-glycosylation, which has important implications for therapeutic applications.

Latest Patents

Adam Tibbles holds a patent for "Engineered O-glycosylation in recombinant polypeptides and uses thereof." This invention relates to recombinant polypeptide therapeutics that feature an engineered O-linked amino acid glycosylation sequence. These sequences are covalently linked to O-glycans, allowing for the production of O-glycosylated polypeptides in mammalian cells. This process enables the presentation of both natural and unnatural O-glycan structures through metabolic labeling. He has 1 patent to his name.

Career Highlights

Adam Tibbles is currently employed at Medimmune Limited, where he continues to advance his research in recombinant therapeutics. His work is pivotal in enhancing the efficacy and specificity of therapeutic proteins, which can lead to improved treatment options for various diseases.

Collaborations

Throughout his career, Adam has collaborated with esteemed colleagues, including Emmanuel Rossy and Daniel Ramsay Higazi. These partnerships have fostered a collaborative environment that promotes innovation and the sharing of ideas in the field of biotechnology.

Conclusion

Adam Tibbles is a prominent figure in the realm of recombinant polypeptide therapeutics, with a focus on engineered O-glycosylation. His contributions are shaping the future of therapeutic development, making significant strides in the biotechnology industry.

Profile summary based on public USPTO records.